Abstract
Melanoma is a life threatening disease with a growing incidence rate. It is estimated that 9840 patients will die from melanoma in 2014. Despite numerous attempts for treating metastatic melanoma, conventional therapies including systemic chemotherapy or immunotherapy, either as single agents or combined, have not been promising. The most cytotoxic agents have low molecular weight, which leads to rapid excretion, nonspecific distribution, and poor therapeutic index. Therefore, they may even increase toxicity due to their non-specific action on healthy tissue that can exacerbate the malady. To provide optimum effective concentration, multiple-dose drug administration is required, which again can increase the incidence of adverse effects. Recent developments in drug delivery systems are able to improve the drug efficacy and safety, and offer more promising approaches in treating melanoma. Recent researches have shed more light on the advantages of novel drug loaded carrier systems versus free drugs. Most of these animal studies, reported improvement in treatment efficacy and survival rate using novel carrier systems. This is related to the ability of these systems in enhancing the anticancer effect by modifying drug pharmacokinetics and biodistribution, selective target delivery of the agents to the diseased tissue and their ability to cross the biological barriers. In this paper, it is attempted to illustrate the potentials of novel strategies in treatment of melanoma incorporating drug delivery systems versus conventional therapies.
Keywords: Gene therapy, iontophoresis, immunotoxin, liposomes, melanoma, metastasis, nanoparticles, novel drug delivery system, photodynamic therapy, ultrasound, vaccination.
Current Drug Targets
Title:The Recent Progresses on The Improved Therapy of Melanoma by Novel Drug Delivery Systems
Volume: 15 Issue: 9
Author(s): Somayeh Taymouri and Jaleh Varshosaz
Affiliation:
Keywords: Gene therapy, iontophoresis, immunotoxin, liposomes, melanoma, metastasis, nanoparticles, novel drug delivery system, photodynamic therapy, ultrasound, vaccination.
Abstract: Melanoma is a life threatening disease with a growing incidence rate. It is estimated that 9840 patients will die from melanoma in 2014. Despite numerous attempts for treating metastatic melanoma, conventional therapies including systemic chemotherapy or immunotherapy, either as single agents or combined, have not been promising. The most cytotoxic agents have low molecular weight, which leads to rapid excretion, nonspecific distribution, and poor therapeutic index. Therefore, they may even increase toxicity due to their non-specific action on healthy tissue that can exacerbate the malady. To provide optimum effective concentration, multiple-dose drug administration is required, which again can increase the incidence of adverse effects. Recent developments in drug delivery systems are able to improve the drug efficacy and safety, and offer more promising approaches in treating melanoma. Recent researches have shed more light on the advantages of novel drug loaded carrier systems versus free drugs. Most of these animal studies, reported improvement in treatment efficacy and survival rate using novel carrier systems. This is related to the ability of these systems in enhancing the anticancer effect by modifying drug pharmacokinetics and biodistribution, selective target delivery of the agents to the diseased tissue and their ability to cross the biological barriers. In this paper, it is attempted to illustrate the potentials of novel strategies in treatment of melanoma incorporating drug delivery systems versus conventional therapies.
Export Options
About this article
Cite this article as:
Taymouri Somayeh and Varshosaz Jaleh, The Recent Progresses on The Improved Therapy of Melanoma by Novel Drug Delivery Systems, Current Drug Targets 2014; 15 (9) . https://dx.doi.org/10.2174/1389450115666140619125701
DOI https://dx.doi.org/10.2174/1389450115666140619125701 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Anabolic Treatments in Osteoporosis
Current Drug Safety Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy TGF Beta Inhibition for Cancer Therapy
Current Cancer Drug Targets A2A Adenosine Receptor Agonists and their Potential Therapeutic Applications. An Update
Current Medicinal Chemistry Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Inflammasomes – A Mini-Review
Current Immunology Reviews (Discontinued) Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Recent Patents on Thiazole Derivatives Endowed with Antitumor Activity
Recent Patents on Anti-Cancer Drug Discovery Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response
Current Pharmaceutical Design Advances in the Chemistry and Pharmacology of Ecteinascidins, A Promising New Class of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Is Effective and Safe a Radiochemotherapy Approach in Elderly Cancer Patients? A Review
Anti-Cancer Agents in Medicinal Chemistry Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Inhibiting the Enzymes of the Endothelin and Renin-Angiotensin Systems in Cancer
Current Enzyme Inhibition Suppression of Cancer Invasiveness by Dietary Compounds
Mini-Reviews in Medicinal Chemistry Identification of Inflammatory, Metabolic, and Cell Survival Pathways Contributing to Cerebral Small Vessel Disease by Postmortem Gene Expression Microarray
Current Neurovascular Research Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy Iodine in Mammary and Prostate Pathologies
Current Chemical Biology Meet Our Associate Editor:
Current Molecular Medicine Injectable Thermosensitive Chitosan/Glycerophosphate-Based Hydrogels for Tissue Engineering and Drug Delivery Applications: A Review
Recent Patents on Drug Delivery & Formulation Infectivity Selective Adenovirus Based on High-throughput Adenoviral Ligand Library Screening
Current Cancer Therapy Reviews